Literature DB >> 32930758

Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.

Elsbeth D M Rouers1,2, Patricia C J Bruijning-Verhagen1,2, Pieter G M van Gageldonk1, Josephine A P van Dongen2, Elisabeth A M Sanders1,3, Guy A M Berbers1.   

Abstract

Importance: The standard schedule of national immunization programs for infants may not be sufficient to protect extremely and very preterm infants. Objective: To evaluate the immunogenicity of routine vaccinations administered to preterm infants. Design, Setting, and Participants: A multicenter, prospective, observational cohort study of preterm infants stratified according to gestational age recruited from 8 hospitals across the Netherlands between October 2015 and October 2017, with follow-up until 12 months of age (October 2018). In total, 296 premature infants were enrolled and compared with a control group of 66 healthy term infants from a 2011 study, immunized according to the same schedule with the same vaccines. Exposures: Three primary doses of the diphtheria-tetanus toxoids-acellular pertussis-inactivated poliomyelitis-Haemophilus influenza type b-hepatitis B combination vaccine were given at 2, 3, and 4 months after birth followed by a booster at 11 months and a 10-valent pneumococcal conjugate vaccine at 2, 4, and 11 months after birth. Main Outcomes and Measures: Primary end points were (1) proportion of preterm infants who achieved IgG antibody against vaccine antigens at concentrations above the internationally defined threshold for protection after the primary series and booster dose and (2) serum IgG geometric mean concentrations after the primary series and booster vaccination. Proportions and geometric mean concentrations were compared in preterm infants and the control group of term infants.
Results: Of 296 preterm infants (56.1% male; mean gestational age, 30 weeks), complete samples before vaccination, 1 month after the primary series, and 1 month after the booster were obtained from 220 preterm infants (74.3%). After the primary series, the proportion of preterm infants across all gestational age groups who achieved protective IgG antibody levels against pertussis toxin, diphtheria, tetanus and 6 of 10 pneumococcal serotypes varied between 83.0% and 100%, Haemophilus influenzae type b between 34.7% and 46.2% (40.6% among all preterm infants overall), and pneumococcal serotypes 4, 6B, 18C, and 23F between 45.8% and 75.1%. After the booster dose, protective antibody levels were achieved in more than 95% of all preterm groups, except for Haemophilus influenzae type b (88.1%). In general, geometric mean concentrations of all vaccine-induced antibodies were significantly lower in all preterm infants vs term infants, except for pertussis toxin and pneumococcal serotypes 4 and 19F after the primary series and booster vaccination. Conclusions and Relevance: Among preterm infants, administration of routine vaccinations during the first year of life was associated with protective antibody levels against most antigens in the majority of infants after the primary series and booster, except for Haemophilus influenzae type b. However, antibody concentrations were generally lower among preterm infants compared with historical controls.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32930758      PMCID: PMC7492917          DOI: 10.1001/jama.2020.12316

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.

Authors:  Felix Omeñaca; José Garcia-Sicilia; Pilar García-Corbeira; Reyes Boceta; Alejandro Romero; Gloria Lopez; Rafael Dal-Ré
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

2.  Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.

Authors:  Daan Barug; Inge Pronk; Marlies A van Houten; Florens G A Versteegh; Mirjam J Knol; Jan van de Kassteele; Guy A M Berbers; Elisabeth A M Sanders; Nynke Y Rots
Journal:  Lancet Infect Dis       Date:  2019-03-27       Impact factor: 25.071

3.  Timeliness of immunisations in preterm infants in the Netherlands.

Authors:  Elsbeth D M Rouers; Guy A M Berbers; Josephine A P van Dongen; Elisabeth A M Sanders; Patricia Bruijning-Verhagen
Journal:  Vaccine       Date:  2019-08-20       Impact factor: 3.641

4.  The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis.

Authors:  Merryn Voysey; Dominic F Kelly; Thomas R Fanshawe; Manish Sadarangani; Katherine L O'Brien; Rafael Perera; Andrew J Pollard
Journal:  JAMA Pediatr       Date:  2017-07-01       Impact factor: 16.193

5.  13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.

Authors:  Federico Martinón-Torres; Hanna Czajka; Kimberly J Center; Jacek Wysocki; Ewa Majda-Stanislawska; Felix Omeñaca; Enrique Bernaola Iturbe; Daniel Blazquez Gamero; Ana Concheiro-Guisán; Francisco Gimenez-Sanchez; Leszek Szenborn; Peter C Giardina; Scott Patterson; William C Gruber; Daniel A Scott; Alejandra Gurtman
Journal:  Pediatrics       Date:  2015-03-16       Impact factor: 7.124

6.  Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines.

Authors:  M H Slack; D Schapira; R J Thwaites; M Burrage; J Southern; N Andrews; R Borrow; D Goldblatt; E Miller
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

7.  Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine.

Authors:  Karin E M Elberse; Irina Tcherniaeva; Guy A M Berbers; Leo M Schouls
Journal:  Clin Vaccine Immunol       Date:  2010-02-03

8.  Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger
Journal:  Vaccine       Date:  2007-02-21       Impact factor: 3.641

9.  Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine.

Authors:  Els van Westen; Mirjam J Knol; Alienke J Wijmenga-Monsuur; Irina Tcherniaeva; Leo M Schouls; Elisabeth A M Sanders; Cecile A C M van Els; Guy A M Berbers; Nynke Y Rots
Journal:  Vaccines (Basel)       Date:  2018-12-11

10.  Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants.

Authors:  Jens U Ruggeberg; Clare Collins; Paul Clarke; Nik Johnson; Ruchi Sinha; Neil Everest; John Chang; Elaine Stanford; Paul Balmer; Ray Borrow; Sarah Martin; Michael J Robinson; E Richard Moxon; Andrew J Pollard; Paul T Heath
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

View more
  2 in total

Review 1.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Authors:  Vanessa Bianconi; Francesco Violi; Francesca Fallarino; Pasquale Pignatelli; Amirhossein Sahebkar; Matteo Pirro
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 2.  Immunization of preterm infants: current evidence and future strategies to individualized approaches.

Authors:  Mats Ingmar Fortmann; Johannes Dirks; Sybelle Goedicke-Fritz; Johannes Liese; Michael Zemlin; Henner Morbach; Christoph Härtel
Journal:  Semin Immunopathol       Date:  2022-08-03       Impact factor: 11.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.